BNP Paribas Financial Markets Makes New Investment in Sensus Healthcare, Inc. (NASDAQ:SRTS)

BNP Paribas Financial Markets purchased a new position in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,851 shares of the company’s stock, valued at approximately $47,000.

A number of other institutional investors also recently modified their holdings of SRTS. Dimensional Fund Advisors LP raised its stake in shares of Sensus Healthcare by 30.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company’s stock valued at $2,620,000 after acquiring an additional 88,953 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Sensus Healthcare by 81.2% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company’s stock valued at $1,039,000 after acquiring an additional 67,269 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Sensus Healthcare by 99.6% in the fourth quarter. Marshall Wace LLP now owns 132,286 shares of the company’s stock valued at $915,000 after acquiring an additional 65,994 shares during the last quarter. O Shaughnessy Asset Management LLC raised its stake in shares of Sensus Healthcare by 65.1% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 93,248 shares of the company’s stock valued at $645,000 after acquiring an additional 36,785 shares during the last quarter. Finally, Integrated Quantitative Investments LLC bought a new position in shares of Sensus Healthcare in the fourth quarter valued at approximately $251,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Price Performance

Shares of Sensus Healthcare stock opened at $4.83 on Wednesday. The firm has a market cap of $79.43 million, a P/E ratio of 12.08 and a beta of 1.30. The firm has a 50 day simple moving average of $4.62 and a 200 day simple moving average of $5.94. Sensus Healthcare, Inc. has a fifty-two week low of $4.01 and a fifty-two week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.20). The company had revenue of $8.34 million during the quarter, compared to analyst estimates of $7.23 million. Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. On average, sell-side analysts expect that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on SRTS. Wall Street Zen cut shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Maxim Group cut their target price on shares of Sensus Healthcare from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, May 19th. Lake Street Capital cut their target price on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Sensus Healthcare in a report on Friday, April 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Sensus Healthcare Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.